Drug Transporter (DT) Information

General Information of DT
DT ID DTD0258
Gene Name SLC2A3
Protein Name Glucose transporter type 3, brain
Gene ID
6515
UniProt ID
P11169
TCDB ID
2.A.1.1.91
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 4ZW9_A

Identity: 99.787%

Minimized Score: -1416.541 kcal/mol

Detail: Structure Info

Synonyms GLUT-3; GLUT3; SLC2A3; Solute carrier family 2, facilitated glucose transporter member 3
DT Family Major Facilitator Superfamily (MFS)
Sugar Porter (SP) Family
Tissue Specificity Highly expressed in brain. Expressed in manytissues.
Function This transporter facilitates glucose transport and mediates the uptake of various other monosaccharides across the cell membrane. Mediates the uptake of glucose, 2-deoxyglucose, galactose, mannose, xylose and fucose, and probably also dehydroascorbate. Does not mediate fructose transport.
Endogenous Substrate(s) Glucose
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
2-Deoxyglucose
 Phase 1/2 Drug Info Cancer 2A00-2F9Z [1]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Glucose
5793
EM Info Unclear experiment used for identifying this EM [2]
References
1 Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J Cell Physiol. 2011 Dec;226(12):3286-94.
2 Shengui Sansheng San Ameliorates Cerebral Energy Deficiency via Citrate Cycle After Ischemic Stroke. Front Pharmacol. 2019 Apr 23;10:386.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.